Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 3/20 | 0.69 |
| ▸ | RAB9A | P51151 | 11/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.67 |
| ▸ | NPC1 | O15118 | 8/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 7/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.59 |
| ▸ | RELA | Q04206 | 2/20 | 0.59 |
| ▸ | AR | P10275 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29085894 | 0.87 | RAB9A (0.65) | MPLRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL31084655 | 0.87 | MPL (0.67) | MPLRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL25243665 | 0.87 | MPL (0.67) | MPLRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL1689576 | 0.84 | RAB9A (0.66) | MPLRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL1801175 | 0.84 | MPL (0.63) | MPLRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL10087446 | 0.84 | ALDH1A1 (0.61) | MPLRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL25242184 | 0.84 | RAB9A (0.61) | MPLRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL2762257 | 0.84 | MPL (0.63) | MPLRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL474270 | 0.84 | MPL (0.63) | MPLRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL128039 | 0.82 | MPL (1.00) | MPLRAB9AALDH1A1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731206-A2 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | Veralox Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20250066345-A1 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | Cadrenal Therapeutics, Inc. | 2025-02-27 | — | — | US | disclosed |
| CN-115466229-B | Para-amidobenzenesulfonyl compound and application thereof | 上海中医药大学 | 2025-01-24 | — | — | CN | disclosed |
| WO-2024264032-A2 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | VERALOX THERAPEUTICS INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| CN-119013013-A | Compositions and methods of use for treating 12-lipoxygenase (12-LOX) -mediated diseases | 维拉洛斯治疗公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4452251-A1 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | Veralox Therapeutics Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-118344304-A | Ibuprofen derivative and preparation method and application thereof | 华南农业大学 | 2024-07-16 | — | — | CN | disclosed |
| WO-2023122494-A1 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | VERALOX THERAPEUTICS (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122494-A1 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | VERALOX THERAPEUTICS (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230089368-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES S.A.S. (FR) | 2023-03-23 | — | — | US | disclosed |
| WO-2007070600-A2 | N-(5-MEMBERED HETEROAROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1794156-A2 | TROMBOPOIETIN RECEPTOR AGONISTS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2007054474-A1 | 2-(BENZIMIDAZOL-1-YL)-N-(4-PHENYLTHIAZOL-2-YL) ACETAMIDE DERIVATIVES USEFUL IN TREATMENT OF TRPV1 RELATED DISORDERS | N.V. ORGANON (NL) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105920-A1 | 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives | AKZO NOBEL N.V. (NL) | 2007-05-10 | — | — | US | disclosed |
| WO-2006117211-A2 | UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF | PROSKELIA SAS (FR) | 2006-11-09 | — | — | WO | disclosed |
| US-7026334-B1 | Thiazolidine compounds and pharmaceutical compositions exhibiting thrombopoietin receptor agonism | SHIONOGI & CO., LTD. (JP) | 2006-04-11 | — | — | US | disclosed |
| WO-2006033005-A2 | THROMBOPOIETIN RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20030134859-A1 | PPAR-gamma modulator | SANKYO COMPANY, LIMITED (JP) | 2003-07-17 | — | — | US | disclosed |
| EP-1277729-A1 | PPAR (GAMMA) MODULATORS | Sankyo Company, Limited (JP) | 2003-01-22 | — | — | EP | disclosed |
| EP-1207155-A1 | DRUG COMPOSITIONS EXHIBITING THROMBOPOIETIN AGONISM | SHIONOGI & CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105920-A1 | 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives | TRPV1, TRPV3, TRPV4 | MPL 4780/4885RAB9A 3153/4885ALDH1A1 825/4885 |
| US-20230089368-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | CKMT1A; CKMT1B, TNNC1, UBQLN2 | MPL 4648/4885RAB9A 4298/4885ALDH1A1 1264/4885 |
| US-20030134859-A1 | PPAR-gamma modulator | PPARG, PPARA, PPARD | MPL 364/4885RAB9A 1179/4885ALDH1A1 583/4885 |
| US-20250066345-A1 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | ALOX12, LOX, ALOX15 | MPL 286/4885RAB9A 2773/4885ALDH1A1 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.